Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 938-925-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Key studies: OECD Guideline 471 (Bacterial Reverse Mutation), 473 (Chromosome Aberration) and 476 (Mammalian Cell Gene Mutation). GLP studies. The test substance appeared to be not mutagenic in the Ames test and in a chromosome aberration study and it was negative in a Mouse Lymphoma assay with and without metabolic activation.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From january 30, 2012 to March 8, 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- Histidine mutation :
TA1537: hisC3076, TA98: hisD3052/R-factor*, TA1535: hisG46, TA100: hisG46/R-factor*
*: R-factor = plasmid pKM101 (increases error-prone DNA repair). - Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Species / strain / cell type:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix
- Test concentrations with justification for top dose:
- Experiment 1: 3, 10, 33, 100, 333, 1000, 3330 and 5000 μg/plate
Experiment 2: 33, 100, 333, 1000, 3330 and 5000 μg/plate - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO; ethanol; physiol. saline
- Untreated negative controls:
- yes
- Remarks:
- (The vehicle of the test substance, which was ethanol)
- Negative solvent / vehicle controls:
- yes
- Remarks:
- (Saline)
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- Without metabolic activation Migrated to IUCLID6: TA1535
- Untreated negative controls:
- yes
- Remarks:
- (The vehicle of the test substance, which was ethanol)
- Negative solvent / vehicle controls:
- yes
- Remarks:
- (DMSO)
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- With metabolic activation Migrated to IUCLID6: TA1535
- Untreated negative controls:
- yes
- Remarks:
- (The vehicle of the test substance, which was ethanol)
- Negative solvent / vehicle controls:
- yes
- Remarks:
- (DMSO)
- Positive controls:
- yes
- Positive control substance:
- other: ICR-191
- Remarks:
- With and without metabolic activation
- Untreated negative controls:
- yes
- Remarks:
- (The vehicle of the test substance, which was ethanol)
- Negative solvent / vehicle controls:
- yes
- Remarks:
- (DMSO)
- Positive controls:
- yes
- Positive control substance:
- 2-nitrofluorene
- Remarks:
- With and without metabolic activation Migrated to IUCLID6: TA98
- Untreated negative controls:
- yes
- Remarks:
- (The vehicle of the test substance, which was ethanol)
- Negative solvent / vehicle controls:
- yes
- Remarks:
- (DMSO)
- Positive controls:
- yes
- Positive control substance:
- methylmethanesulfonate
- Remarks:
- With and without metabolic activation Migrated to IUCLID6: TA100
- Untreated negative controls:
- yes
- Remarks:
- (The vehicle of the test substance, which was ethanol)
- Negative solvent / vehicle controls:
- yes
- Remarks:
- (DMSO)
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- Remarks:
- With and without metabolic activation Migrated to IUCLID6: WP2uvrA
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in agar (plate incorporation). Top agar in top agar tubes was melted by heating to 45°C. The following solutions were successively added to 3 ml molten top agar: 0.1 ml of a fresh bacterial culture (10E9 cells/ml) of one of the tester strains, 0.1 ml of a dilution of the test substance in ethanol and either 0.5 ml S9-mix (in case of activation assays) or 0.5 ml 0.1 M phosphate buffer (in case of non-activation assays). The ingredients were mixed on a Vortex and the content of the top agar tube was poured onto a selective agar plate. After solidification of the top agar, the plates were inverted and incubated in the dark at 37.0 ± 1.0 °C for 48 ± 4 h. After this period revertant colonies, histidine independent (His+), for Salmonella typhimurium bacteria and tryptophan independent (Trp+) for Escherichia coli were counted.
NUMBER OF REPLICATIONS: Triplicates
DETERMINATION OF CYTOTOXICITY
- Method: The plates were examinated for a reduction of the bacterial background lawn, the increase in the size of the microcolonies and the reduction of the revertant colonies. - Evaluation criteria:
- A test substance is considered negative (not mutagenic) in the test if:
a) The total number of revertants in tester strain TA100 is not greater than two (2) times the concurrent control, and the total number of revertants in tester strains TA1535, TA1537, TA98 or WP2uvrA is not greater than three (3) times the concurrent vehicle control.
b) The negative response should be reproducible in at least one independently repeated experiment.
A test substance is considered positive (mutagenic) in the test if:
a) The total number of revertants in tester strain TA100 is greater than two (2) times the concurrent control, or the total number of revertants in tester strains TA1535, TA1537, TA98 or WP2uvrA is greater than three (3) times the concurrent vehicle control.
b) In case a repeat experiment is performed when a positive response is observed in one of the tester strains, the positive response should be reproducible in at least one independently repeated experiment.
The preceding criteria were not absolute and other modifying factors might enter into the final evaluation decision. - Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- (at a dose level of 3330 and 5000µg/plate, only in experiment 2 and in absence of S-9 mix for strain TA100)
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING/SCREENING STUDIES:
The dose range of the test material used in the preliminary toxicity study was 3, 10, 33, 100, 333, 1000, 3330 and 5000 μg/plate in the absence and presence of S9-mix. The test material exhibited toxicity at 3330 and 5000 μg/plate to the strain of Salmonella used (TA100). In tester strain WP2uvrA, no toxicity was observed at any of the dose levels tested.
COMPARISON WITH HISTORICAL CONTROL DATA:
The negative and strain-specific positive control values were within the laboratory historical control data ranges indicating that the test conditions were adequate and that the metabolic activation system functioned properly. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results: negative
Based on the results of this study it is concluded that the test substance is not mutagenic in the Salmonella typhimurium reverse mutation assay and in the Escherichia coli reverse mutation assay. - Executive summary:
Evaluation of the mutagenic activity of the test substance in the Salmonella typhimurium and the Escherichia coli reverse mutation assay (with independent repeat) was determinated according to OECD 471, EC B.13/14 Guidelines and with GLP. Four histidine-requiring strains of Salmonella typhimurium (TA1535, TA1537, TA98 and TA100) and a tryptophan-requiring strain of Escherichia coli (WP2uvrA) were used for the assay. The test was performed in two independent experiments in the presence and absence of S9-mix (5% (v/v) S9 fraction in expertiment 1 and 10% (v/v) S9 franction in experiment 2). The dose range was determined in a prelimirary toxicity assay and was 3 to 5000µg/plate in the first experiment. The experiment was repeated using a dose range of 33 to 5000 µg/plate.
The negative and strain-specific positive control values were within the laboratory historical control data ranges indicating that the test conditions were adequate and that the metabolic activation system functioned properly.
Based on the results of this study it is concluded that Reaction products of n-octanol and acrylic acid, first distillation pitch is not mutagenic in the Salmonella typhimurium reverse mutation assay and in the Escherichia coli reverse mutation assay.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From January 12, 2012 to March 21, 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian chromosome aberration test
- Species / strain / cell type:
- lymphocytes: Blood was collected from healthy adult, non-smoking, male volunteers. Dose range finding study: First cytogenetic assay: age 31, AGT = 13.4 h; Second cytogenetic assay: age 26, AGT = 15.3 h
- Details on mammalian cell type (if applicable):
- - Type and identity of media: Culture medium consisted of RPMI 1640 medium (Invitrogen Corporation), supplemented with 20% (v/v) heat-inactivated (56°C; 30 min) foetal calf serum (Invitrogen Corporation), L-glutamine (2 mM) (Invitrogen Corporation), penicillin/streptomycin (50 U/mL and 50 μg/mL respectively) (Invitrogen Corporation) and 30 U/mL heparin (Sigma, Zwijndrecht, The Netherlands).
- Properly maintained: yes (at a temperature of 37.0 ± 1.0°C and 5.0 ± 0.5% CO2 in air). - Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix
- Test concentrations with justification for top dose:
- -Experiment 1: 10, 33 and 100 µg/mL culture medium (3 h exposure time, 24 h fixation time) with and without S9-mix.
-Experiment 2: Without S9-mix : 10, 100, 150, 200, 250 and 300 μg/mL culture medium (24 h and 48 h exposure time, 24 h and 48 h fixation time). With S9-mix : 10, 33 and 100 μg/mL culture medium (3 h exposure time, 48 h fixation time). - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: Test substance solvent: Dimethyl sulfoxide (DMSO); positive control solvent: Hanks’ Balanced Salt Solution (HBSS) (Invitrogen Corporation, Breda, The Netherlands), without calcium and magnesium.
- Untreated negative controls:
- yes
- Remarks:
- (DMSO)
- Positive controls:
- yes
- Positive control substance:
- mitomycin C
- Remarks:
- Without metabolic activation (-S9-mix) Migrated to IUCLID6: 0.5 μg/mL for a 3 h exposure period, 0.2 μg/mL for a 24 h exposure period and 0.1 μg/mL for a 48 h exposure period.
- Untreated negative controls:
- yes
- Remarks:
- (DMSO)
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- With metabolic activation (+S9-mix) Migrated to IUCLID6: 10 μg/mL for a 3 h exposure period (24 h fixation time).
- Details on test system and experimental conditions:
- METHOD OF APPLICATION:
Experiment 1 : After 3 h exposure to the test substance in the absence or presence of S9-mix, the cells were separated from the exposure medium by centrifugation (5 min, 365 g). The supernatant was removed and cells were rinsed with 5 mL HBSS. After a second centrifugation step, HBSS was removed and cells were resuspended in 5 mL culture medium and incubated for another 20 - 22 h (24 h fixation time). The cells that were exposed for 24 h and 48 h in the absence of S9-mix were not rinsed after exposure but were fixed immediately (24 h and 48 h fixation time).
Experiment 2: After 3 h exposure, the cells exposed to the test substance in the presence of S9-mix were separated from the exposure medium by centrifugation (5 min, 365 g). The supernatant was removed and the cells were rinsed once with 5 mL of HBSS and incubated in 5 mL culture medium for another 44 - 46 h (48 h fixation time). The cells that were treated for 24 h and 48 h in the absence of S9-mix were not rinsed after exposure but were fixed immediately after 24 h and 48 h (24 h and 48 h fixation time). Appropriate negative and positive controls were included in the second cytogenetic assay.
DURATION
- Exposure duration: Experiment 1: 3h; Experiment 2: 3, 24 and 48 h.
- Fixation time (start of exposure up to fixation or harvest of cells): Experiment 1: 24 h; Experiment 2: 24 and 48h.
SPINDLE INHIBITOR (cytogenetic assays): During the last 2.5 - 3 h of the culture period, cell division was arrested by the addition of the spindle inhibitor colchicine (0.5 μg/mL medium).
STAIN (for cytogenetic assays): 10 - 30 min with 5% (v/v) Giemsa (Merck) solution in tap water.
NUMBER OF REPLICATIONS: duplicate culture
NUMBER OF CELLS EVALUATED: One hundred metaphase chromosome spreads per culture; only metaphases containing 46 ± 2 centromeres (chromosomes) were analysed.
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index. The mitotic index of each culture was determined by counting the number of metaphases per 1000 cells. Chromosomes of metaphase spreads were analysed from those cultures with an inhibition of the mitotic index of about 50% or above whereas the mitotic index of the lowest dose level was approximately the same as the mitotic index of the solvent control.
OTHER EXAMINATIONS:
- Determination of polyploidy: yes, but was not counted as an aberration.
- Determination of endoreplication: no - Evaluation criteria:
- A chromosome aberration test is considered acceptable if it meets the following criteria:
a) The number of chromosome aberrations found in the solvent control cultures should reasonably be within the laboratory historical control data range.
b) The positive control substances should produce a statistically significant (Chi-square test, onesided, p < 0.05) increase in the number of cells with chromosome aberrations.
c) A homogeneous response between the replicate cultures is observed.
d) A possible precipitate present on the slides should not interfere with the scoring of chromosome aberrations. - Statistics:
- The incidence of aberrant cells (cells with one or more chromosome aberrations, gaps included or excluded) for each exposure group outside the laboratory historical control data range was compared to that of the solvent control using Chi-square statistics.
- Species / strain:
- lymphocytes: blood samples were obtained from healthy male subjects.
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING/SCREENING STUDIES: At the dose range finding study at the 24 h and 48 h continuous exposure time blood cultures were reated with 1, 3, 10, 33, 100, 333 and 1000 μg test substance/mL culture medium without S9-mix. The test substance was tested beyond the limit of solubility to obtain adequate toxicity data. At a concentration of 100 μg/mL test substance precipitated in the culture medium.
COMPARISON WITH HISTORICAL CONTROL DATA: The number of cells with chromosome aberrations found in the solvent control cultures was within the laboratory historical control data range. The number of polyploid cells and cells with endoreduplicated chromosomes in the solvent control cultures was within the laboratory historical control data range. The positive control chemicals (MMC-C and CP) both produced statistically significant increases in the frequency of aberrant cells. It was therefore concluded that the test conditions were adequate and that the metabolic activation system (S9-mix) functioned properly. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results: negative
The test substanceis not clastogenic in human lymphocytes. - Executive summary:
Evaluation of the ability of the test substance to induce chromosome aberrations in cultured peripheral human lymphocytes was determinated according to OECD 473, EC B.10 Guidelines and with GLP. The chromosome aberrations were evaluated in the presence and absence of a metabolic activation system (phenobarbital and ß-naphthoflavone induced rat liver S9-mix). The possible clastogenicity of the test substance was tested in two independent experiments.
In the first cytogenetic assay, the test substance was tested up to 100 μg/mL for a 3 h exposure time with a 24 h fixation time in the absence and presence of 1.8% (v/v) S9-fraction; and showed precipitated in the culture medium at this dose level.
In the second cytogenetic assay, the test substance was tested up to 250 μg/mL for a 24 h continuous exposure time with a 24 h fixation time and up to 200 μg/mL for a 48 h continuous exposure time with a 48 h fixation time in the absence of S9-mix. Appropriate toxicity was reached at these dose levels. In the presence of S9-mix the test substance was tested up to 100 μg/mL for a 3 h exposure time with a 48 h fixation time and showed precipitated in the culture medium at this dose level.
Positive control chemicals, MMC-C and CP, both produced a statistically significant increase in the incidence of cells with chromosome aberrations, indicating that the test conditions were adequate and that the metabolic activation system (S9-mix) functioned properly.
The test substance did not induce a statistically significant or biologically relevant increase in the number of cells with chromosome aberrations and did not presented any effects on the number of polyploid cells and cells with endoreduplicated chromosomes in the absence and presence of S9-mix in either of the two independently repeated experiments.
Therefore it can be concluded that the test substance does not disturb mitotic processes and cell cycle progression and does not induce numerical chromosome aberrations.
In conclusion, the test substance is not clastogenic in human lymphocytes.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From January 10, 2012 to March 5, 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Principles of method if other than guideline:
- “International Workshop on Genotoxicity Tests Workgroup” (the IWGT), published in the literature (Clive et al., 1995, Moore et al., 1999, 2000, 2002, 2003, 2006 and 2007).
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- Thymidine-kinase locus (TK-locus) in L5178Y mouse lymphoma cells
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- - Type and identity of media: RPMI 1640 Hepes buffered medium (Dutch modification) (Invitrogen Corporation) containing penicillin/streptomycin (50 U/ml and 50 μg/ml, respectively) (Invitrogen), 1 mM sodium pyruvate (Sigma) and 2 mM L-glutamin (Invitrogen Corporation).
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes
- Periodically checked for karyotype stability: no
- Periodically "cleansed" against high spontaneous background: no - Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver S9-mix induced by a combination of phenobarbital and ß-naphthoflavone
- Test concentrations with justification for top dose:
- Dose range finding test:
3 to 333 μg/ml in the absence of S9-mix with a 3 and 24 hour treatment period and in the presence of S9-mix with a 3 hour treatment period.
Experiment 1:
in the absence and presence of 8% (v/v) S9-mix: 0.03, 0.1, 0.3, 1, 3, 10, 33 and 100 μg/ml exposure medium.
Experiment 2:
in the absence and presence of 12% (v/v) S9-mix: 0.03, 0.1, 0.3, 1, 3, 10, 33 and 100 μg/ml exposure medium. - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO.
- Untreated negative controls:
- yes
- Remarks:
- The solvent for the test article, i.e. dimethyl sulfoxide.
- Positive controls:
- yes
- Positive control substance:
- methylmethanesulfonate
- Remarks:
- Without metabolic activation (-S9-mix) Migrated to IUCLID6: 15 and 5 μg/ml for a 3 and 24 hours treatment period, respectively
- Untreated negative controls:
- yes
- Remarks:
- The solvent for the test article, i.e. dimethyl sulfoxide.
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- With metabolic activation (+S9-mix) Migrated to IUCLID6: 7.5 μg/ml
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration:
Experiment 1: in the absence and presence of (8%) S9-mix (3 hour treatment period)
Experiment 2: in the absence (24 hour treatment period) and presence of (12%) S9-mix(3 hour treatment period)
- Expression time (cells in growth medium): 2 days
- Selection time (if incubation with a selection agent): 11 or 12 days
SELECTION AGENT (mutation assays): 5 μg/ml trifluorothymidine (TFT)
STAIN (for cytogenetic assays): 0.5 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
NUMBER OF REPLICATIONS:
- Solvent controls: Duplo cultures
- Treatment groups and positive control: Single cultures
NUMBER OF CELLS EVALUATED: 9.6 x 10E5 cells/concentration
DETERMINATION OF CYTOTOXICITY
- Method: relative suspension growth (dose range finding test) and relative total growth (mutation experiments) - Evaluation criteria:
- A mutation assay was considered acceptable if it met the following criteria:
a) The absolute cloning efficiency of the solvent controls (CEday2) is between 65 and 120%. An acceptable number of surviving cells (10E6) could be analysed for expression of the TK mutation.
b) The spontaneous mutation frequency in the solvent control is ≥ 50 per 10E6 survivors and ≤ 170 per 10E6 survivors.
c) The growth rate (GR) over the 2-day expression period for the negative controls should be between 8 and 32 (3 hours treatment) and between 32-180 (24 hours treatment).
d) The mutation frequency of MMS should not be below 500 per 10E6 survivors, and for CP not below 700 per 10E6 survivors.
The global evaluation factor (GEF) has been defined by the IWGT as the mean of the negative/solvent MF distribution plus one standard deviation. For the micro well version of the assay the GEF is 126.
A test substance is considered positive (mutagenic) in the mutation assay if it induces a MF of more than MF(controls) + 126 in a dose-dependent manner. An observed increase should be biologically relevant and will be compared with the historical control data range.
A test substance is considered equivocal (questionable) in the mutation assay if no clear conclusion for positive or negative result can be made after an additional confirmation study.
A test substance is considered negative (not mutagenic) in the mutation assay if:
a) None of the tested concentrations reaches a mutation frequency of MF(controls) + 126.
b) The results are confirmed in an independently repeated test. - Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: No
- Effects of osmolality: No
- Precipitation: precipitating dose level was observed at 333 μg/ml in the dose range finding test.
RANGE-FINDING/SCREENING STUDIES:
- No toxicity in the RSG was observed up to and including the highest test substance concentration of 333 μg/ml compared to the suspension growth of the solvent control (in absence and presence of S9-mix at 3 and 24hours).
COMPARISON WITH HISTORICAL CONTROL DATA:
The spontaneous mutation frequencies in the solvent-treated control cultures were between the minimum and maximum value of the historical control data range and within the acceptability criteria of this assay, with the exception of mutation frequency of the positive control in the absence of S9-mix (second experiment).
ADDITIONAL INFORMATION ON CYTOTOXICITY:
No toxicity was observed and all dose levels were evaluated in the absence and presence of S9-mix. - Remarks on result:
- other: strain/cell type: L5178Y/TK+/--3.7.2C mouse lymphoma cells
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results: negative
The test substance is not mutagenic in the TK mutation test system. - Executive summary:
Evaluation of the mutagenic activity of the test substance in an in vitro mammalian cell gene mutation test with L5178Y mouse lymphoma cells was deterinated according to the OECD 476, EC B.17 Guidelines and with GLP. The test was performed in two independent experiments in the absence and presence of S9-mix (rat liver S9-mix induced by a combination of phenobarbital and ß-naphthoflavone).
Although the mutation frequency of the positive control in the absence of S9-mix (second experiment) was not within the acceptability criteria, the mutagenic response was more than 8 times greater than the concurrent solvent control values, therefore the validity of the test was considered to be not affected.
The test substance did not induce a significant increase in the mutation frequency in the first experiment. This result was confirmed in a second experiment with modifications in the duration of treatment time (in the absence of S9-mix) and with modifications in the concentration of the S9 for metabolic activation (in the presence of S9-mix).
It is concluded that Reaction products of n-octanol and acrylic acid, first distillation pitch is not mutagenic in the mouse lymphoma L5178Y test system.
Referenceopen allclose all
Table 1. Experiment 1: Mutagenic response of Reaction products of n-octanol and acrylic acid, first distillation pitch in the Salmonella typhimurium reverse mutation assay and in the Escherichia coli reverse mutation assay.
Dose Mean number of revertant colonies/3 replicate plates (± S.D.) with (ug/plate) different strains ofSalmonella typhimuriumand oneEscherichia colistrain |
|||||
|
TA1535 |
TA1537 |
TA98 |
TA100 |
WP2uvrA |
Without S9-mix |
|||||
Positive control |
807 ± 25 |
848 ± 22 |
858 ± 40 |
812 ± 17 |
977 ± 9 |
Solvent control |
10 ± 0 |
6 ± 2 |
23 ± 3 |
107 ± 3 |
21 ± 5 |
3 |
|
|
|
90 ± 6 |
23 ± 5 |
10 |
|
|
|
100 ± 9 |
25 ± 5 |
33 |
7 ± 1 |
4 ± 2 |
13 ± 1 |
101 ± 21 |
27 ± 4 |
100 |
10 ± 3 |
4 ± 2 |
17 ± 3 |
99 ± 10 |
17 ± 3 |
333 |
9 ± 2 |
4 ± 1 |
14 ± 3 |
101 ± 10 |
19 ± 5 |
1000 |
8 ± 3 |
5 ± 2 |
18 ± 2 |
87 ± 13 |
18 ± 1 |
3330 |
8 ± 2 |
3 ± 2 |
18 ± 3 |
50 ± 7 |
21 ± 3 |
5000 SP |
6 ± 2 |
2 ± 2 |
11 ± 1 |
17 ± 5 |
20 ± 3 |
With S9-mix1 |
|||||
Positive control |
252 ± 9 |
394 ± 23 |
886 ± 20 |
955 ± 51 |
381 ± 35 |
Solvent control |
7 ± 2 |
5 ± 2 |
22 ± 2 |
146 ± 13 |
21 ± 2 |
3 |
|
|
|
92 ± 10 |
22 ± 4 |
10 |
|
|
|
86 ± 11 |
20 ± 3 |
33 |
7 ± 2 |
6 ± 1 |
21 ± 0 |
95 ± 4 |
19 ± 2 |
100 |
7 ± 2 |
6 ± 2 |
23 ± 1 |
87 ± 3 |
19 ± 1 |
333 |
7 ± 4 |
4 ± 2 |
20 ± 2 |
99 ± 12 |
20 ± 2 |
1000 |
8 ± 3 |
6 ± 4 |
21 ± 2 |
89 ± 12 |
19 ± 5 |
3330 |
9 ± 5 |
4 ± 1 |
21 ± 3 |
70 ± 7 |
18 ± 3 |
5000 SP |
7 ± 2 |
3 ± 2 |
19 ± 3 |
41 ± 13 |
16 ± 3 |
Solvent control: 0.1 ml ethanol
1 The S9-mix contained 5% (v/v) S9 fraction
SP Slight Precipitate
Table 2. Experiment 2: Mutagenic response of Reaction products of n-octanol and acrylic acid, first distillation pitch in the Salmonella typhimurium reverse mutation assay and in the Escherichia coli reverse mutation assay.
Dose Mean number of revertant colonies/3 replicate plates (± S.D.) with (ug/plate) different strains ofSalmonella typhimuriumand oneEscherichia colistrain |
|||||
|
TA1535 |
TA1537 |
TA98 |
TA100 |
WP2uvrA |
Without S9-mix |
|||||
Positive control |
698 ± 45 |
543 ± 61 |
989 ± 45 |
842 ± 63 |
977 ± 104 |
Solvent control |
5 ± 1 |
4 ± 1 |
15 ± 4 |
90 ± 14 |
13 ± 4 |
33 |
6 ± 2 |
3 ± 1 |
14 ± 3 |
84 ± 7 |
13 ± 2 |
100 |
6± 2 |
4 ± 1 |
11± 3 |
81 ± 9 |
17 ± 3 |
333 |
5 ± 1 |
3 ± 2 |
14 ± 3 |
85± 2 |
17± 3 |
1000 |
8 ± 0 |
3 ± 1 |
14 ± 2 |
71 ± 6 |
14± 3 |
3330 |
4 ± 3 |
3 ± 1 |
13 ± 6 |
56 ± 8 |
12 ± 4 |
5000 SP |
5± 2 |
3 ± 1 |
13± 3 |
42 ± 7 |
20± 2 |
With S9-mix1 |
|||||
Positive control |
171 ± 13 |
329 ± 31 |
715 ± 23 |
1138 ± 183 |
429 ± 13 |
Solvent control |
4 ± 2 |
3 ± 1 |
19 ± 3 |
115 ± 7 |
15 ± 2 |
33 |
6 ± 2 |
7 ± 1 |
23 ± 3 |
111 ± 26 |
14 ± 4 |
100 |
5 ± 1 |
5± 3 |
21 ± 3 |
99 ± 13 |
18 ± 2 |
333 |
7 ± 1 |
2± 1 |
22 ± 5 |
118 ± 27 |
18 ± 3 |
1000 |
7 ± 1 |
3 ± 2 |
21 ± 2 |
110 ± 14 |
21 ± 2 |
3330 SP |
6± 1 |
4 ± 2 |
18 ± 3 |
107 ± 7 |
17 ± 1 |
5000 SP |
5 ± 1 |
2 ± 2 |
19 ± 5 |
109 ± 8 |
11 ± 4 |
Solvent control: 0.1 ml ethanol
1 The S9-mix contained 10% (v/v) S9 fraction
SP Slight Precipitate
Table 1. Chromosome aberrations in human lymphocyte cultures treated with Reaction products of n-octanol and acrylic acid, first distillation pitch in the absence of S9-mix in the first cytogenetic assay (3 h exposure time, 24 h fixation time). | |||||||||||||||||
Conc | DMSO | 10 | 33 | 100 | MMC-C | ||||||||||||
(1.0% v/v) | µg/mL | µg/mL | µg/mL | 0.5 µg/mL | |||||||||||||
Culture | A | B | A+B | A | B | A+B | A | B | A+B | A | B | A+B | A | B | A+B | ||
Mitotic index (%) | 100 | 101 | 97 | 85 | 87 | ||||||||||||
No. of | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | ||
cells scored | |||||||||||||||||
No. of cells with aberrations | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 21 | ***) | ||
(+gaps)a) | 34 | ||||||||||||||||
No. of cells with aberrations (- gaps) | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 20 | ***) | ||
33 | |||||||||||||||||
g´ | 1 | 1 | |||||||||||||||
g” | |||||||||||||||||
b` | 1 | 11 | 17 | ||||||||||||||
b” | 1 | 4 | |||||||||||||||
m` | |||||||||||||||||
m” | |||||||||||||||||
exch. | 1 | ||||||||||||||||
dic | |||||||||||||||||
d´ | |||||||||||||||||
misc. | |||||||||||||||||
Total aberr (+gaps) | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 22 | |||||||
Total aberr | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 21 | |||||||
(-gaps) | |||||||||||||||||
a) Abbreviations used for various types of aberrations. | |||||||||||||||||
misc. = (miscellaneous) aberrations not belonging to the ones mentioned above. | |||||||||||||||||
*)Significantly different from control group (Chi-square test), * P < 0.05, ** P < 0.01 or *** P < 0.001. | |||||||||||||||||
Table 2. Chromosome aberrations in human lymphocyte cultures treated with Reaction products of n-octanol and acrylic acid, first distillation pitch in the presence of S9-mix in the first cytogenetic assay (3 h exposure time, 24 h fixation time). | |||||||||||||||||
Conc | DMSO | 10 | 33 | 100 | CP | ||||||||||||
(1.0% v/v) | µg/mL | µg/mL | µg/mL | 10 µg/mL | |||||||||||||
Culture | A | B | A+B | A | B | A+B | A | B | A+B | A | B | A+B | A | B | A+B | ||
Mitotic index (%) | 100 | 94 | 92 | 84 | 49 | ||||||||||||
No. of cells scored | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | ||
No. of cells with aberrations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 21 | 24 | ***) | ||
(+gaps)a) | 45 | ||||||||||||||||
No. of cells with aberrations (- gaps) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 21 | 24 | ***) | ||
45 | |||||||||||||||||
g´ | |||||||||||||||||
g” | |||||||||||||||||
b` | 2 | 17 | 19 | ||||||||||||||
b” | 3 | 7 | |||||||||||||||
m` | |||||||||||||||||
m” | |||||||||||||||||
exch. | 1 | 1 | |||||||||||||||
dic | |||||||||||||||||
d´ | |||||||||||||||||
misc. | poly | poly | |||||||||||||||
Total aberr (+gaps) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 21 | 27 | |||||||
Total aberr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 21 | 27 | |||||||
(-gaps) | |||||||||||||||||
a) Abbreviations used for various types of aberrations. | |||||||||||||||||
misc. = (miscellaneous) aberrations not belonging to the ones mentioned above. | |||||||||||||||||
The numerical variations polyploidy (poly) was not counted as an aberration. | |||||||||||||||||
*) Significantly different from control group (Chi-square test), * P < 0.05, ** P < 0.01 or *** P < 0.001. | |||||||||||||||||
Table 3. Chromosome aberrations in human lymphocyte cultures treated with Reaction products of n-octanol and acrylic acid, first distillation pitch in the absence of S9-mix in the second cytogenetic assay (24 h exposure time, 24 h fixation time). | |||||||||||||||||
Conc | DMSO | 100 | 200 | 250 | MMC-C | ||||||||||||
(1.0% v/v) | µg/mL | µg/mL | µg/mL | 0.2 µg/mL | |||||||||||||
Culture | A | B | A+B | A | B | A+B | A | B | A+B | A | B | A+B | A | B | A+B | ||
Mitotic index (%) | 100 | 101 | 66 | 47 | 96 | ||||||||||||
No. of cells scored | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | ||
No. of cells with aberrations | 0 | 2 | 2 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 2 | 17 | 18 | |||
(+gaps)a) | |||||||||||||||||
***) | |||||||||||||||||
35 | |||||||||||||||||
No. of cells with aberrations (- gaps) | 0 | 2 | 2 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 2 | 17 | 18 | |||
***) | |||||||||||||||||
35 | |||||||||||||||||
g´ | |||||||||||||||||
g” | |||||||||||||||||
b` | 1 | 1 | 3 | 4 | |||||||||||||
b” | 2 | 1 | 1 | 12 | 15 | ||||||||||||
m` | |||||||||||||||||
m” | |||||||||||||||||
exch. | 3 | 1 | |||||||||||||||
dic | |||||||||||||||||
d´ | |||||||||||||||||
misc. | |||||||||||||||||
Total aberr (+gaps) | 0 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 18 | 20 | |||||||
Total aberr (-gaps) | 0 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 18 | 20 | |||||||
a) Abbreviations used for various types of aberrations. | |||||||||||||||||
misc. = (miscellaneous) aberrations not belonging to the ones mentioned above. | |||||||||||||||||
*) Significantly different from control group (Chi-square test), * P < 0.05, ** P < 0.01 or *** P < 0.001. | |||||||||||||||||
Table 4. Chromosome aberrations in human lymphocyte cultures treated with Reaction products of n-octanol and acrylic acid, first distillation pitch in the absence of S9-mix in the second cytogenetic assay (48 h exposure time, 48 h fixation time). | |||||||||||||||||
Conc | DMSO | 10 | 100 | 200 | MMC-C | ||||||||||||
(1.0% v/v) | µg/mL | µg/mL | µg/mL | 0.1 µg/mL | |||||||||||||
Culture | A | B | A+B | A | B | A+B | A | B | A+B | A | B | A+B | A | B | A+B | ||
Mitotic index (%) | 100 | 95 | 67 | 44 | 82 | ||||||||||||
No. of cells scored | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | ||
No. of cells with aberrations | 3 | 2 | 5 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 22 | |||
(+gaps)a) | |||||||||||||||||
***) | |||||||||||||||||
42 | |||||||||||||||||
No. of cells with aberrations (- gaps) | 3 | 2 | 5 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 22 | |||
***) | |||||||||||||||||
42 | |||||||||||||||||
g´ | |||||||||||||||||
g” | |||||||||||||||||
b` | 1 | 1 | 2 | 6 | |||||||||||||
b” | 2 | 1 | 15 | 12 | |||||||||||||
m` | |||||||||||||||||
m” | |||||||||||||||||
exch. | 1 | 5 | 5 | ||||||||||||||
dic | |||||||||||||||||
d´ | |||||||||||||||||
misc. | |||||||||||||||||
Total aberr (+gaps) | 3 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 22 | 23 | |||||||
Total aberr (-gaps) | 3 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 22 | 23 | |||||||
a) Abbreviations used for various types of aberrations. | |||||||||||||||||
misc. = (miscellaneous) aberrations not belonging to the ones mentioned above. | |||||||||||||||||
*) Significantly different from control group (Chi-square test), * P < 0.05, ** P < 0.01 or *** P < 0.001. | |||||||||||||||||
Table 5. Chromosome aberrations in human lymphocyte cultures treated with Reaction products of n-octanol and acrylic acid, first distillation pitch in the presence of S9-mix in the second cytogenetic assay (3 h exposure time, 48 h fixation time). | |||||||||||||||||
Conc | DMSO | 10 | 33 | 100 | CP | ||||||||||||
(1.0% v/v) | µg/mL | µg/mL | µg/mL | 10 µg/mL | |||||||||||||
Culture | A | B | A+B | A | B | A+B | A | B | A+B | A | B | A+B | A | B | A+B | ||
Mitotic index (%) | 100 | 98 | 95 | 98 | -b) | ||||||||||||
No. of cells scored | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | 100 | 100 | 200 | ||
No. of cells with aberrations | 1 | 2 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 17 | ***) | ||
(+gaps)a) | 39 | ||||||||||||||||
No. of cells with aberrations (- gaps) | 1 | 2 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 17 | ***) | ||
39 | |||||||||||||||||
g´ | 1 | ||||||||||||||||
g” | |||||||||||||||||
b` | 2 | 17 | 6 | ||||||||||||||
b” | 1 | 1 | 10 | 11 | |||||||||||||
m` | |||||||||||||||||
m” | |||||||||||||||||
exch. | 1 | 4 | |||||||||||||||
dic | |||||||||||||||||
d´ | |||||||||||||||||
misc. | |||||||||||||||||
Total aberr (+gaps) | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 29 | 21 | |||||||
Total aberr (-gaps) | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 28 | 21 | |||||||
a) Abbreviations used for various types of aberrations. | |||||||||||||||||
misc. = (miscellaneous) aberrations not belonging to the ones mentioned above. | |||||||||||||||||
b)CP was fixed after 24 hours. Therefore, the mitotic index could not be calculated as percentage of control. | |||||||||||||||||
*) Significantly different from control group (Chi-square test), * P < 0.05, ** P < 0.01 or *** P < 0.001. |
Table 1. Experiment 1: Cytotoxic and mutagenic response of Reaction products of n-octanol and acrylic acid, first distillation pitch in the mouse lymphoma L5178Y test system.
dose |
RSG |
CEday2 |
RSday2 |
RTG |
mutation frequency |
||
(µg/ml) |
(%) |
(%) |
(%) |
(%) |
per 106survivors total |
||
|
|
|
|
|
Total |
( small |
large) |
without metabolic activation 3 hours treatment |
|||||||
SC1 SC2 |
100 |
80 71 |
100 |
100 |
50 66 |
( 26 ( 30 |
22) 34) |
0.03 |
107 |
65 |
86 |
92 |
70 |
( 34 |
34) |
0.1 |
112 |
90 |
119 |
133 |
73 |
( 30 |
41) |
0.3 |
117 |
71 |
94 |
110 |
61 |
( 31 |
28) |
1 |
124 |
63 |
83 |
103 |
65 |
( 32 |
32) |
3 |
113 |
70 |
93 |
105 |
49 |
( 24 |
24) |
10 |
97 |
110 |
145 |
141 |
67 |
( 22 |
43) |
33 |
118 |
79 |
104 |
123 |
59 |
( 32 |
26) |
100(1) |
100 |
63 |
83 |
84 |
78 |
( 39 |
37) |
MMS |
83 |
27 |
35 |
29 |
899 |
( 364 |
482) |
With 8% (v/v) metabolic activation 3 hours treatment |
|||||||
SC1 SC2 |
100 |
74 115 |
100 |
100 |
96 68 |
( 36 ( 32 |
56 ) 33) |
0.03 |
99 |
108 |
115 |
114 |
65 |
( 30 |
33) |
0.1 |
120 |
85 |
90 |
109 |
74 |
( 34 |
38) |
0.3 |
110 |
88 |
93 |
102 |
71 |
( 23 |
46) |
1 |
112 |
72 |
77 |
86 |
58 |
( 31 |
26) |
3 |
96 |
101 |
107 |
103 |
47 |
( 17 |
29) |
10 |
124 |
105 |
112 |
138 |
54 |
( 26 |
26) |
33 |
113 |
115 |
122 |
138 |
44 |
( 15 |
28) |
100(1) |
122 |
95 |
101 |
124 |
76 |
( 25 |
49) |
CP |
61 |
55 |
58 |
35 |
1351 |
( 543 |
563) |
Note: all calculations were made without rounding off
RSG = Relative Suspension Growth; CE = Cloning Efficiency; RS = Relative Survival; RTG = Relative Total Growth; SC = Solvent control = Ethanol; MMS = Methylmethanesulfonate;
CP = Cyclophosphamide
(1) = Condensation products of cyclopentanone and pentaldehyde, fractionation pitch precipitated in the exposure medium
Table 2. Experiment 2: Cytotoxic and mutagenic response of Reaction products of n-octanol and acrylic acid, first distillation pitch in the mouse lymphoma L5178Y test system.
dose |
RSG |
CEday2 |
RSday2 |
RTG |
mutation frequency |
||
(µg/ml) |
(%) |
(%) |
(%) |
(%) |
per 106survivors total |
||
|
|
|
|
|
Total |
( small |
large) |
without metabolic activation 24 hours treatment |
|||||||
SC1 |
100 |
105 89 |
100 |
100 |
62 92 |
( 33 ( 36 |
27) 52) |
SC2 |
|||||||
0.03 |
106 |
91 |
94 |
100 |
69 |
( 40 |
27) |
0.1 |
68 |
94 |
97 |
66 |
77 |
( 32 |
43) |
0.3 |
108 |
99 |
103 |
111 |
37 |
( 18 |
18) |
1 |
123 |
84 |
86 |
106 |
81 |
( 32 |
46) |
3 |
126 |
80 |
83 |
104 |
44 |
( 20 |
24) |
10 |
133 |
97 |
100 |
132 |
35 |
( 13 |
21) |
33 |
98 |
81 |
84 |
83 |
86 |
( 27 |
56) |
100(1) |
72 |
91 |
94 |
68 |
59 |
( 17 |
40) |
MMS |
131 |
83 |
85 |
112 |
494 |
( 227 |
218) |
With 12% (v/v) metabolic activation 3 hours treatment |
|||||||
SC1 SC2 |
100 |
93 115 |
100 |
100 |
97 92 |
( 32 ( 32 |
61) 55) |
0.03 |
124 |
123 |
119 |
148 |
52 |
( 24 |
26) |
0.1 |
126 |
98 |
95 |
119 |
75 |
( 30 |
43) |
0.3 |
115 |
98 |
95 |
109 |
71 |
( 23 |
46) |
1 |
97 |
95 |
92 |
89 |
83 |
( 40 |
40) |
3 |
97 |
93 |
89 |
87 |
80 |
( 32 |
44) |
10 |
108 |
98 |
95 |
102 |
82 |
( 24 |
55) |
33 |
113 |
121 |
117 |
132 |
49 |
( 25 |
23) |
100(1) |
100 |
108 |
104 |
105 |
74 |
( 29 |
42) |
CP |
74 |
77 |
74 |
55 |
960 |
( 342 |
447) |
Note: all calculations were made without rounding off
RSG = Relative Suspension Growth; CE = Cloning Efficiency; RS = Relative Survival; RTG = Relative Total Growth;
SC = Solvent control = Ethanol; MMS = Methylmethanesulfonate; CP = Cyclophosphamide
[1] = Condensation products of cyclopentanone and pentaldehyde, fractionation pitch precipitated in the exposure medium
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Key study: Ames Test:
The reverse mutation was carried out according to OECD Guideline 471 (GLP study). The test substance is not mutagenic in Salmonella typhimurium strains TA 1535, TA 1537, TA 98 and, TA 100 and E. Coli WP2 uvr A with and without metabolic activation. Cytotoxicity was only observed in tester strain TA100 in the absence of S9 -mix in the second experiment, at 3330 and 5000 µg/plate.
Key study: Chromosome aberrations:
The chromosome aberration in cultured peripheral human lymphocytes was carried out according to OEDC Guideline 473 (GLP study). No chromosomal aberrations were induced in human lymphocytes tested with and without metabolic activation. No toxicity was observed up to and including the highest precipitating tested dose in the absence and presence of S9 -mix at 3, 24 and 48 hours exposure and 24 and 48 hours fixation time.
Key study: Mammalian cell gene mutation:
The mutagenic activity of test substance was carried out according to the OECD Guideline 476 (GLP study) showing no effects on the thymidine kinase locus in L5178Y mouse lymphoma cells. No toxicity was observed up to and including the highest test substance concentration of 100 µg/mL in the absence and presence of S9 -mix.
Justification for classification or non-classification
Based on all information available, Reaction products of n-octanol and acrylic acid, first distillation pitch does not have to be classified for genotoxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.